Former senior executive at Bausch Health Companies Inc
- Key trends and developments in the generics pharmaceutical space
- Bausch Health’s (NYSE: BHC) product pipeline and capabilities post spin-offs
- Competitive positioning of major players surrounding Bausch Health, such as Johnson & Johnson (NYSE: JNJ) and Teva Pharmaceuticals (TLV: TEVA)
- Cost reduction efforts and ability to generate free cash flow
- 2022 outlook, turnaround potential and business risks
Gain access to Premium Content
Submit your details to access up to 5 Forum Transcripts or to request a complimentary one week trial.